Generic Name and Formulations:
Lacosamide 10mg/mL; strawberry-flavored; contains phenylalanine 0.32mg/20mL.
Company:
UCB Inc.
Indications for VIMPAT ORAL SOLUTION:
Adjunct in partial-onset seizures.
Adult Dose for VIMPAT ORAL SOLUTION:
Oral soln: use calibrated measuring device. Inj: may give without diluting, or mix in appropriate diluent and give by IV infusion over 30–60min. For oral and inj: ≥17yrs: initially 50mg twice daily; may increase at weekly intervals by 100mg/day in 2 divided doses . Maintenance dose: 200–400mg/day. Renal impairment (CrCl≤30mL/min), ESRD, mild-moderate hepatic impairment: max 300mg/day. Consider supplemental dose (50%) after hemodialysis. Avoid abrupt cessation (withdraw over 1 week).
Children's Dose for VIMPAT ORAL SOLUTION:
<17yrs: not established.
See Also:
VIMPAT
VIMPAT INJECTION
Pharmacological Class:
Sodium channel inactivator.
Warnings/Precautions:
Severe hepatic impairment: not recommended. Cardiac conduction disturbances (eg, marked 1st or 2nd degree AV block, sick sinus syndrome unless paced). Severe cardiac disease (eg, myocardial ischemia, heart failure). Monitor for suicidal ideation, depression. Diabetic neuropathy. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Interactions:
Caution with other drugs that cause PR prolongation.
Adverse Reactions:
Dizziness, ataxia, diplopia, headache, nausea, syncope; PR interval prolongation, multiorgan hypersensitivity reaction (rare).
Note:
Note: To enroll in the UCB AED Pregnancy Registry call (888) 537-7734.
How Supplied:
Tabs—60; Oral soln—465mL; Single-use vials (20mL)—10
